Carvolix joins key Euronext indices, marking a new milestone in its capital markets profile

Aix-en-Provence, March 23, 2026 – 5:45 pm. CET – Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 – Ticker: CVX – “Carvolix” or the “Company”), a French commercial and clinical-stage medical technology company specializing in the international development and industrialization of breakthrough AI-driven mini-robots and biomimetic implants, announces its inclusion in the CAC® Small, CAC® Mid & Small and CAC® All-Tradable indices, following the latest quarterly review by Euronext.

This decision is effective as of March 23, 2026. This inclusion is expected to enhance the Company’s visibility, improve trading liquidity and broaden its investor base, notably through increased exposure to index-tracking funds.

Sébastien Ladet, CEO comments: “Our inclusion in these Euronext indices marks a milestone in Carvolix’s development. It reflects the growing recognition of our technology platform and strengthens our visibility among institutional investors. This step supports our ambition to accelerate the deployment of our AI driven mini robotic solutions to democratize access to complex procedure in structural heart diseases and stroke.”

About Carvolix

Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases and brain strokes, world's leading causes of mortality and disability. Carvolix develops novel AI and imaging driven mini robots that make complex procedures doable by interventional cardiologists, as well as biomimetics heart valves.

Contacts: